tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Ascendis Pharma price target raised to $227 from $194 at TD Cowen

TD Cowen analyst Yaron Werber raised the firm’s price target on Ascendis Pharma (ASND) to $227 from $194 and keeps a Buy rating on the shares. The firm said they posted a strong Q2 Yorvipath beat but a Skytrofa miss due to foreign exchange headwinds.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1